Search Results - "LEBOVITZ, Harold E"

Thiazolidinediones: the Forgotten Diabetes Medications by Lebovitz, Harold E.

“…Purpose of Review Thiazolidinediones (TZDs) are the only pharmacologic agents that specifically treat insulin resistance. The beneficial effects of TZDs on the…”
Get full text

Point: Visceral Adiposity Is Causally Related to Insulin Resistance by Lebovitz, Harold E, Banerji, Mary Ann

“…Several lines of evidence that support the hypothesis that visceral adipose tissue is the major contributor in causing insulin resistance and the metabolic…”
Get full text

Insulin resistance - a common link between type 2 diabetes and cardiovascular disease by Lebovitz, Harold E.

“…Evidence suggests that diabetes and cardiovascular disease (CVD) may share an underlying cause(s), a theory known as the ‘common soil’ hypothesis. Insulin…”
Get full text

Differentiating members of the thiazolidinedione class: a focus on safety by Lebovitz, Harold E.

“…Troglitazone, rosiglitazone and pioglitazone are members of the thiazolidinedione (TZD) class – antidiabetic agents that have proven efficacy in the treatment…”
Get full text

Ketosis-Prone Diabetes (Flatbush Diabetes): an Emerging Worldwide Clinically Important Entity by Lebovitz, Harold E., Banerji, Mary Ann

“…Purpose of Review Ketosis-prone diabetes or Flatbush diabetes has been widely recognized as a clinical entity since 1984. Most of the early clinical studies…”
Get full text

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY--CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN--2015--EXECUTIVE SUMMARY by Handelsman, Yehuda, Bloomgarden, Zachary T, Grunberger, George, Umpierrez, Guillermo, Zimmerman, Robert S, Bailey, Timothy S, Blonde, Lawrence, Bray, George A, Cohen, A Jay, Dagogo-Jack, Samuel, Davidson, Jaime A, Einhorn, Daniel, Ganda, Om P, Garber, Alan J, Garvey, W Timothy, Henry, Robert R, Hirsch, Irl B, Horton, Edward S, Hurley, Daniel L, Jellinger, Paul S, Jovanovič, Lois, Lebovitz, Harold E, LeRoith, Derek, Levy, Philip, McGill, Janet B, Mechanick, Jeffrey I, Mestman, Jorge H, Moghissi, Etie S, Orzeck, Eric A, Pessah-Pollack, Rachel, Rosenblit, Paul D, Vinik, Aaron I, Wyne, Kathleen, Zangeneh, Farhad

Get more information

Insulin: potential negative consequences of early routine use in patients with type 2 diabetes by Lebovitz, Harold E

“…At the end of 11 years of treatment, the reduction in vascular complications with insulin was no greater than that with sulfonylureas (9). [...] there is not a…”
Get full text

Treatment of insulin resistance in diabetes mellitus by Lebovitz, Harold E., Banerji, Mary Ann

“…Insulin resistance is a condition in which the glycemic response to insulin is less than normal. The change in insulin sensitivity leads to several sets of…”
Get full text

Type 2 Diabetes: An Overview by Lebovitz, Harold E

“…Type 2 diabetes is a heterogeneous disorder. Clinical expression of the disorder requires both genetic and environmental factors. One theory concerning its…”
Get full text

Effect of the postprandial state on nontraditional risk factors by Lebovitz, Harold E

“…Hyperglycemia is the cause of chronic microvascular complications in diabetes. Increased macrovascular disease occurring in diabetes is multifactorial, with…”
Get full text

Type 2 diabetes mellitus-current therapies and the emergence of surgical options by Lebovitz, Harold E

“…New antidiabetic agents enable many patients with type 2 diabetes mellitus (T2DM) to achieve target HbA 1c levels. However, a range of factors can interfere…”
Get full text

Interventional treatment of obesity and diabetes: An interim report on gastric electrical stimulation by Lebovitz, Harold E.

“…Gastric electrical stimulation has been applied to treat human obesity since 1995. Dilatation of the stomach causes a series of neural reflexes which result in…”
Get full text

Metabolic surgery for type 2 diabetes with BMI <35 kg/m(2) : an endocrinologist's perspective by Lebovitz, Harold E

“…Is bariatric surgery as primary therapy for type 2 diabetes mellitus (T2DM) with body mass index (BMI) <35 kg/m(2) justified? Open-label studies have shown…”
Get full text

Adjunct therapy for type 1 diabetes mellitus by Lebovitz, Harold E

“…Insulin replacement therapy in type 1 diabetes mellitus (T1DM) leads to peripheral hyperinsulinemia, which is associated with potentially serious metabolic…”
Get full text

The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Sitagliptin Monotherapy by FOUQUERAY, Pascale, PIRAGS, Valdis, DIAMANT, Michaela, SCHERNTHANER, Guntram, LEBOVITZ, Harold E, INZUCCHI, Silvio E, BAILEY, Clifford J

“…This 12-week study assessed the efficacy and tolerability of imeglimin as add-on therapy to the dipeptidyl peptidase-4 inhibitor sitagliptin in patients with…”
Get full text

The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy by FOUQUERAY, Pascale, PIRAGS, Valdis, INZUCCHI, Silvio E, BAILEY, Clifford J, SCHERNTHANER, Guntram, DIAMANT, Michaela, LEBOVITZ, Harold E

“…A 12-week study assessed the efficacy and safety of a new oral antidiabetic agent, imeglimin, as add-on therapy in type 2 diabetes patients inadequately…”
Get full text

Correspondence: Response to Letter to the Editor by K Scharf and J Morton by Lebovitz, Harold E.

Get full text

Autoimmune polyglandular syndromes: interplay between the immune and the endocrine systems leading to a diverse set of clinical diseases and new insights into immune regulation by Lebovitz, Harold E

“…During the last 50 years, three major classes of autoimmune polyglandular syndromes (APSs) have been defined, and their characteristics and heritability have…”
Get more information

Incretin-based therapies: facing the realities of benefits versus side effects by Lebovitz, Harold E

Get more information

Treating hyperglycemia in type 2 diabetes: new goals and strategies by Lebovitz, Harold E

“…To achieve glycemic goals in type 2 diabetes, one must usually use combinations of oral agents or oral agents plus insulin. This paper discusses the metabolic…”
Get full text